2014
Macmillan Cancer have recently published a new report that examined the 9 issues that people affected by cancer have told Macmillan matters to them most. The report looks at a range of feedback received and the issues that were identified as having the ...
2014
Back in March this year, we posted a blog about biological therapies for stomach cancer with a focus on the drug Ramicurumab. It has been recently announced that this drug has now been licensed in the USA. The FDA (the organization that assesses new ...
2014
The results of a recent publication in the Annals of Oncology suggest that unlike most cancers, the death rate of pancreatic cancer continues to climb. It is likely that one of the key reasons for this is that it is usually diagnosed at an advanced stage, ...
2014
Last month Dr Rohit Lal, Independent Oncology’s specialist in Thoracic cancers, had expressed his concern at the decision by NICE to withhold funding for Tarceva® (erlotinib) for non-small cell lung cancer (NSCLC) when first-line treatment fails. ...